A Phase 1, First-in-human, Randomized, Double-blind, Placebo controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DWP213388 after Single and Multiple Ascending Oral Dose Administration in Healthy Adult Subjects
DWP213388 will be administered to the study subjects, according to a randomized, double-blind, and placebo-controlled design. The administration will be a single or multiple oral doses for healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
TEAE
Incidence and severity
Time frame: up to 7 days from the last dosing
12-lead ECG
PR interval, QRS interval, RR interval, QT interval, and QTcF
Time frame: up to 7 days from the last dosing
Cmax
Drug concentration in Blood and urine
Time frame: up to 72 hours from the last dosing
AUC
Area under curve
Time frame: up to 72 hours from the last dosing
CL/F
Clearance
Time frame: up to 72 hours from the last dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.